Skip to content
Beacon

TDNAT. Rowe Price Biotech ETF

Grow my moneyNewRanked #3,061 of 3,062 in this goal

Seeks long-term capital appreciation.

Launched 2026

Annual Cost

—

Fund Size

—

Return (1Y)

N/A

Track Record

0 month

#6,060 of 6,062 · young

Performance

Annualized total return

1 Year

N/A

3 Years

N/A

5 Years

N/A

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Active selection

Sector

Health care

Focus

Biotech & Genomics

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
N/A
Max drawdown
-2.0%Mild

Worst peak-to-trough loss

Sharpe (3Y)
Unavailable

Needs 3+ years of history

Sortino (3Y)
Not yet

Needs 3+ years of history

Listing

Exchange
NASDAQ Global Select Market

Full fund details

Objective
Seeks long-term capital appreciation.
Strategy
Invests primarily in securities of biotechnology companies, focusing on health care innovations and therapies. Concentrates on U.S. common stocks but may include foreign stocks, targeting companies across various stages of drug development.
Inception date
September 17, 2026

Next steps

Save TDNA to compare it with other funds, or start building a portfolio.

See other funds for this goal

Data updated on 2026-09-19